Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab

References

• SpringateDAParisiRKontopantelisEReevesDGriffithsCEAshcroftDMIncidence, prevalence and mortality of patients with psoriasis: a UK population-based cohort studyBr J Dermatol2016 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• GriffithsCEMBarkerJNPathogenesis and clinical features of psoriasisLancet2007370958326327117658397
   PubMed Web of Science ®Google Scholar
• ZachariaeHPrevalence of joint disease in patients with psoriasis: implications for therapyAm J Clin Dermatol20034744144712814334
   PubMed Web of Science ®Google Scholar
• NiCChiuMWPsoriasis and comorbidities: links and risksClin Cosmet Investig Dermatol20147119132
   PubMedGoogle Scholar
• RappSRFeldmanSRExumMLFleischerABJrReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol199941340140710459113
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline CNational Institute for Health and Clinical Excellence: Guidance 2012Psoriasis: Assessment and Management of PsoriasisLondonRoyal College of Physicians (UK)
   Google Scholar
• JinnaSStroberBAnti-interleukin-17 treatment of psoriasisJ Der-matolog Treat2016274311315
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535627299809
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two Phase 3 randomised trialsLancet2015386999354155126072109
   PubMed Web of Science ®Google Scholar
• CampaMMansouriBWarrenRMenterAA review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasisDermatol Ther (Heidelb)20166111226714681
   PubMed Web of Science ®Google Scholar
• GirolomoniGMrowietzUPaulCPsoriasis: rationale for targeting interleukin-17Br J Dermatol2012167471772422716185
   PubMed Web of Science ®Google Scholar
• MahilSKCaponFBarkerJNGenetics of psoriasisDermatol Clin201533111125412779
   PubMed Web of Science ®Google Scholar
• LonnbergASZachariaeCSkovLTargeting of interleukin-17 in the treatment of psoriasisClin Cosmet Investig Dermatol20147251259
   PubMedGoogle Scholar
• GaspariAATyringSNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: Mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsDermatol Ther201528417919326201310
   PubMed Web of Science ®Google Scholar
• NweSMChamplainAHGordonKBRationale and early clinical data on IL-17 blockade in psoriasisExpert Rev Clin Immunol20139767768223899238
   PubMed Web of Science ®Google Scholar
• ArizaMEWilliamsMVWongHKTargeting IL-17 in psoriasis: from cutaneous immunobiology to clinical applicationClin Immunol2013146213113923314273
   PubMed Web of Science ®Google Scholar
• MartinDATowneJEKricorianGThe emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findingsJ Invest Dermatol20131331172622673731
   PubMed Web of Science ®Google Scholar
• GooderhamMPosso-De Los RiosCJRubio-GomezGAPappKInterleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a reviewSkin Therapy Lett201520115
   Google Scholar
• LowesMAKikuchiTFuentes-DuculanJPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cellsJ Invest Dermatol200812851207121118200064
   PubMed Web of Science ®Google Scholar
• VuHTTGooderhamMPappKIxekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritisExpert Rev Clin Pharmacol201691114231433
   PubMed Web of Science ®Google Scholar
• Summary of product characteristicsTaltz 80 mg solution for injection in pre-filled syringe Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003943/WC500205804.pdfAccessed 26/10/2016
   Google Scholar
• LiuLLuJAllanBWGeneration and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17AJ Inflamm Res20169395027143947
   PubMed Web of Science ®Google Scholar
• GenoveseMCVan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum201062492993920131262
   PubMed Web of Science ®Google Scholar
• Callis DuffinKBagelJBukhaloMPhase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)J Eur Acad Dermatol Venereol201631110711327500949
   PubMed Web of Science ®Google Scholar
• KimballABNikaiEZhuBCarlierHYosipovitchGIxekizumab impact on itch severity compared to etanercept and placebo: Results from UNCOVER-2, a Phase 3 trial in patients with moderate-to-severe plaque psoriasisJournal of Investigative Dermatology2015135S19
   PubMed Web of Science ®Google Scholar
• ReichKLeonardiCLebwohlMSustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three Phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)J Dermtol Treat201616
   Google Scholar
• SaekiHNakagawaHIshiiTEfficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasisJ EurAcad Dermatol Venereol201529611481155
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two Phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• RothsteinBGottliebASecukinumab for treating plaque psoriasisExpert Opin Biol Ther201616111912826577956
   PubMed Web of Science ®Google Scholar
• PappKAReichKPaulCA prospective Phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisBr J Dermatol2016175227328626914406
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyA Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S) Available from https://clinicaltrials.gov/ct2/show/NCT02561806?term=ixekizumab&rank=12Accessed October 26, 2016
   Google Scholar
• 25th EADV Congress. Late-breaking insight: Ixekizumab vs usteki-numab head-to-head data in psoriasis. [Video on the Internet]1042016 https://www.youtube.com/watch?v=pTasylB3yAU,2016Accessed January 27, 2017
   Google Scholar
• BlauveltAReichKTsaiTFSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyJ Am Acad Dermatol2016761606927663079
   PubMed Web of Science ®Google Scholar
• LebwohlMStroberBMenterAPhase 3 Studies Comparing Brodalumab with Ustekinumab in PsoriasisN Engl J Med2015373141318132826422722
   PubMed Web of Science ®Google Scholar
• TakeshitaJCallis DuffinKShinDBPatient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical settingJ Am Acad Dermatol201471463364124928705
   PubMed Web of Science ®Google Scholar
• MeasePJvan der HeijdeDRitchlinCTIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the Phase III trial SPIRIT-1Ann Rheum Dis2016
   Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, Phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• ForlowSBSchurrJRKollsJKBagbyGJSchwarzenbergerPOLeyKIncreased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient miceBlood200198123309331411719368
   PubMed Web of Science ®Google Scholar
• YiuZZNGriffithsCEMInterleukin 17-A inhibition in the treatment of psoriasisExpert Rev Clin Immunol20161211426561053
   PubMed Web of Science ®Google Scholar
• FitzpatrickLRInhibition of IL-17 as a pharmacological approach for IBDIn Rev Immunol2013325–6544555
   PubMed Web of Science ®Google Scholar
• HueberWSandsBELewitzkySSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
   PubMed Web of Science ®Google Scholar
• FarahnikBBeroukhimKAbroukMBrodalumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatol Ther (Heidelb)20166211112427221323
   PubMed Web of Science ®Google Scholar
• WarrenRBSmithCHYiuZZDifferential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)J Invest Dermatol2015135112632264026053050
   PubMed Web of Science ®Google Scholar